U.S. Supreme Court agrees to hear dispute over biologic drug sales

A Novartis logo is pictured on its headquarters building in MumbaiBy Andrew Chung NEW YORK (Reuters) – The U.S. Supreme Court on Friday agreed to hear a dispute over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval to begin selling them. The justices will take up an appeal by Novartis AG of a 2015 federal appeals court decision that prevented the Swiss pharmaceutical company from selling its biosimilar version of California-based Amgen Inc's $1-billion-a-year Neupogen until six months after the Food and Drug Administration approved it. Unlike traditional drugs, biologic drugs cannot be copied exactly to make generic versions.

Source: Feed3

Leave a Reply

Your email address will not be published. Required fields are marked *